Stay updated with breaking news from Upenn Gene Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months...
Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with
Relive the Class of 2023's junior year, in which the University transitioned back to in-person life and Liz Magill became the University's ninth president.
Passage Bio, Inc. (NASDAQ:NASDAQ:PASG) Q2 2022 Earnings Conference Call August 04, 2022, 08:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale -...
Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study...